Dechra Pharmaceuticals PLC - Cheshire, England-based veterinary drug maker - European Commission on Friday clears takeover of Dechra by funds managed by EQT Fund Management Sarl, together with Luxinva SA. As a result, all conditions of the offer relating to antitrust and regulatory approvals have been met. Takeover is expected to complete on January 16, and Dechra shares will be cancelled from trading in London from the market open the next day. The offer values Dechra at 3,875 pence per share, or about GBP4.5 billion in total.
Current stock price: 3,854.42p
12-month change: up 45%
By Tom Waite, Alliance News editor
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.